Introduction
============

According to the estimation, there are probably 1,658,370 people suffer from cancer and 589,430 people die of cancer in the United States in 2015[@B1]. In China, the corresponding data were 4,292,000 and 2,814,000 in 2015, respectively, which means cancer is an urgent problem to be solved [@B2]. Several methods such as surgery, radiotherapy, and chemotherapy are widely applied for the clinical treatment of cancer. Irinotecan-based chemotherapy is one of the most used chemotherapies for patients with advanced gastric cancer, ovarian cancer, metastatic colorectal cancer, and other cancers [@B3]-[@B5]. Irinotecan, a camptothecin derivative, is mainly transported into liver by solute carriers and metabolized into ametabolite, SN-38, by a carboxylesterase [@B6]. In turn, SN-38 is glucuronidated by uridinediphosphate (UDP)-glucuronosyltransferases (UGTs) to an inactive form, SN-38G. Lower glucuronidation rates lead to higher SN-38 concentrations, resulting in irinotecan-induced severe toxicity [@B7]. Diarrhea and neutropenia are the most common side effects of irinotecan-based chemotherapy, limiting its application [@B8]. Recent studies have confirmed thatUDP UGT 1A1 play a vital role in the process of glucuronidation [@B9], [@B10].

The UGT1A1\*28 polymorphism contains an extra TA repeat in the 5′-promoter region, whose mutant genotype is A(TA)~7~TAA (TA7/7) and has a wide genotype of A(TA)~6~TAA (TA6/6). Toffoli et al.[@B11] found that UGT1A1\*28 TA7/TA7 genotype is related to a lower glucuronidation ratio. Previous studies investigated the relationship of UGT1A1\*28 with neutropenia and diarrhea and have shown conflicting results. TA6/6 was reported to be a main predictive factor for diarrhea in a study of 56 advanced colorectal carcinoma (CRC) [@B12]. In contrast, some studies found that patients with the TA6/7 or TA7/7 genotypes are more inclined to suffer severe neutropenia and diarrhea [@B13]-[@B16]. However, no correlation was defined between the UGT1A1\*28 polymorphism and neutropenia according to data from Hirata et al.[@B17] and Ferraldeschi et al.[@B18].

To clarify the predictive value of the UGT1A1\*28 polymorphism in patients receiving irinotecan-based chemotherapy, we conducted this study to investigate the impact of the UGT1A1\*28 polymorphism on tumor response and the common toxicities, diarrhea and neutropenia.

Materials and methods
=====================

Publication Search
------------------

Studies were selected by retrieving the Web of Science, PubMed, CNKI, and WanFang databases, up to June 2016. Similar keywords were used in different databases: "UGT1A1\*28" and "diarrhea," "UGT1A1\*28" and "neutropenia," "UGT1A1\*28" and "response," "UGT1A1\*28" and "irinotecan," "UGT1A1\*28" and "CPT-11," and related terms. No language restrictions were applied. All qualified studies were searched and a cross search was also used to identify the remaining relevant studies. When overlapping data exist in different reports, the most complete article was included. Disagreements between two authors will be settled by discussion and consensus.

Selection Criteria
------------------

Studies were included if they fulfilled the following criteria: (a) clinical trials; (b) evaluated the association of the UGT1A1\*28 polymorphism with irinotecan-induced toxicities and chemotherapeutic effect; and (c) contained key information about the number of patients who have severe diarrhea, neutropenia and response to chemotherapy or not. Duplicate studies, review articles, letters, non-original studies, or case reports were excluded.

Data Extraction
---------------

Detailed information of included studies had been extracted and recorded in a standardized table by two reviewers. The following information was recorded: first author\'s surname, year of publication, ethnicity, cancer subtype, methods of mutation detection, number of patients with and without response, severe diarrhea and neutropenia, genotypes were extracted. If these data were not reported, items were marked "NR" (not reported).

Data Synthesis
--------------

This meta-analysis was conducted according to the PRISMA guidelines [@B19]. We used the Newcastle-Ottawa-Scale (NOS) to assess the qualities of including studies and calculated the combined odd ratios (ORs) and 95% confidence intervals (CIs) to evaluate the strength of relationship between the UGT1A1\*28 polymorphism and irinotecan-induced diarrhea or neutropenia under the four models (TA6/7 vs. TA6/6, TA7/7 vs. TA6/6, TA6/7+TA7/7 vs. TA6/6, and TA7/7 vs. TA6/6+TA6/7) [@B20]. The association between tumor response and the UGT1A1\*28 polymorphism was calculated only in the dominant model (TA6/7+TA7/7 vs. TA6/6). Pooled ORs were tested by the Z test, and a *P* value \<0.05 was considered significant. Chi-square test and Q test were used to examine the heterogeneity among the studies. We also performed stratified analysis depending on tumor types (advanced gastric cancer, metastatic non-small cell lung cancer, metastatic colorectal cancer, or others), ethnicity (Asian, Caucasian or mixed people) and study design (retrospective or prospective study). Publication bias were determined by Egger\'s and Begg\'s tests [@B21], [@B22]. Specific methods are described in our pervious study [@B23]. A trim and fill method of adjusting for publication bias was carried out when the *P* value of Egger\'s test was less than 0.05 [@B24]. Trial sequential analysis (TSA) was conducted to calculate the required sample size to get a robust conclusion [@B20]. When P values of two-sided comparisons were less than 0.05, we considered the difference was significant. We performed all the statistical calculations by STATA 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Characteristics of the Studies Included
---------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, we performed the primary literature retrieval using the PubMed, Web of Science, Wanfang, and CNKI databases by the end of June 2016. First, 307 articles were included and 119 articles were excluded after searching for duplicates. Second, we read the titles and abstracts and excluded 78 articles because they were letters, case reports, reviews or reporting about other polymorphisms. Finally, after reading the full-text of all articles, 53 articles were excluded due to lacking of useful data or evaluation about other toxicities and 58 studies from 57 articles including 6087 patients with cancer were found to meet the inclusion criteria.

Among these studies, 16 studies investigated the associations in Caucasians [@B11]-[@B15], [@B18], [@B25]-[@B35], 40 in Asians [@B3], [@B9], [@B16], [@B17], [@B36]-[@B62], and two in mixed population or not reported [@B63], [@B64]. All studies were retrospective or prospective studies, including 29 metastatic colorectal cancer (mCRC) studies, five metastatic non-small cell lung cancer (mNSCLC), three advanced gastric cancer (GC) studies, two SCLC studies, and two advanced esophageal cancer studies and others. Table [1](#T1){ref-type="table"} summarized the basic information of the included studies.

Meta-Analysis of UGT1A1\*28 Polymorphism and Severe Diarrhea
------------------------------------------------------------

There were 44 studies of 4868 patients to evaluate the relationships between the UGT1A1\*28 polymorphism and irinotecan-induced severe diarrhea. As shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, we found the UGT1A1\*28 polymorphism was significantly related to severe diarrhea risk under all comparisons (TA 6/7 vs. TA6/6: OR = 1.56, 95%CI = 1.25-1.96; TA7/7 vs. TA6/6: OR = 3.97, 95%CI = 1.88-8.38; TA 7/7 vs. TA6/7+TA6/6: OR = 3.64, 95%CI = 2.01-6.58), regardless of the study design. By performing the subgroup analysis, we confirmed the relationship in the Asian group (TA6/7 vs. TA6/6: OR = 1.85, 95%CI = 1.37-2.50, *P*\<0.001; TA7/7 vs. TA6/6: OR = 8.98, 95% CI = 5.21-15.47, *P*\<0.001; TA6/7+TA7/7 vs. TA6/6: OR = 2.74, 95%CI = 2.21-3.40, *P*\<0.001; TA 7/7 vs. TA6/6+TA6/7: OR = 8.64, 95%CI = 4.14-18.04, *P*\<0.001) and in Caucasians (TA7/7 vs. TA6/6+TA6/7: OR = 1.62, 95%CI = 1.03-2.53). Stratified analysis according to cancer type was also carried out in this study. Individuals with mCRC carrying the TA7/7 or TA6/7 genotypes had a higher risk of getting diarrhea after irinotecan-based chemotherapy compared with the TA6/6 genotype (TA6/7 vs. TA6/6: OR = 1.60, 95%CI = 1.11-2.31, *P* = 0.011; TA7/7 vs. TA6/6: OR = 3.53, 95%CI = 1.54-8.09, *P* = 0.003). The same risk was also seen in SCLC patients (TA6/7+TA7/7 vs. TA6/6: OR = 3.95, 95%CI = 1.42-11.01, *P* = 0.009; TA7/7 vs. TA6/6+TA6/7: OR = 19.90, 95%CI = 2.57-154.1, *P* = 0.004).

Meta-Analysis of UGT1A1\*28 Polymorphism and Severe Neutropenia
---------------------------------------------------------------

The relationships of the UGT1A1\*28 polymorphism with irinotecan-induced severe neutropenia risk were investigated in 49 studies of 5232 patients. The UGT1A1\*28 polymorphism was significantly related to an increased severe neutropenia incidence (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}, TA 6/7 vs. TA6/6: OR = 1.71, 95%CI = 1.41-2.08; TA7/7 vs. TA6/6: OR = 5.34, 95%CI = 3.05-9.33; TA 7/7 vs. TA6/7+TA6/6: OR = 4.12, 95%CI = 2.36-7.20). Caucasians and Asians with at least one TA7 allele had a higher risk of neutropenia (Caucasians: TA6/7 or TA7/7 vs. TA6/6: OR = 1.84 and 5.67; Asians: TA6/7 or TA7/7 vs. TA6/6: OR = 1.56 and 4.77). In the analysis stratified by cancer type and study design, an association was also found in retrospective and prospective designs, with mCRC patients having the TA7/7 and TA6/7 genotypes (TA6/7 or TA7/7 vs. TA6/6: OR = 1.76 and 5.07) and solid tumor patients with the TA7/7 genotype (TA7/7 vs. TA6/6 or TA6/6+6/7: OR = 7.66 and 6.68).

Meta-Analysis of UGT1A1\*28 Polymorphism and Response
-----------------------------------------------------

Eighteen studies with 2024 patients were assessed to determine the association of the UGT1A1\*28 polymorphism with tumor response to irinotecan-based chemotherapy (Table [4](#T4){ref-type="table"} and Figure [4](#F4){ref-type="fig"}). A partial or complete remission was grouped as a response, while stable tumor or progression was considered no response. A response occurred in patients with at least one mutation allele but not in patients with the wide genotype (TA6/7+TA7/7 vs. TA6/6: OR = 1.20, 95%CI = 1.07-1.34, *P* = 0.016). The association was significant in Caucasians (OR = 1.23, 95%CI = 1.06-1.42, *P* = 0.006), retrospective study designs (OR = 1.54, 95%CI = 1.06-2.23, *P* = 0.022), and mCRC patients (OR = 1.24, 95%CI = 1.05-1.48, *P* = 0.014).

Heterogeneity Analysis
----------------------

There was high heterogeneity among studies evaluating severe diarrhea under the homozygous and recessive comparisons (TA7/7 vs. TA6/6: *P* = 0.007, I^2^= 51.7%; TA7/7 vs. TA6/6+TA6/7: *P*\<0.001, I^2^= 57.6%). We performed meta-regression to explore the sources of heterogeneity. The data indicated that ethnicity and year of publication accounted for 76% and 26% of heterogeneity under the homozygous model and 54% and 41% under the recessive model, respectively (data not shown). There was high heterogeneity among studies of neutropenia under recessive comparison (*P*\<0.001, I^2^= 60.7%). The meta-regression results only revealed that the number of patients represented 25% of the heterogeneity and no other factors were found (data not shown).

Publication Bias
----------------

To detect publication bias in studies that evaluated diarrhea and neutropenia, we performed the Begg and Egger tests (Table [5](#T5){ref-type="table"}). As shown in Table [5](#T5){ref-type="table"}, publication bias was found only among the studies of neutropenia under the dominant model (*P* = 0.027). Next, a trim and fill method was applied and the results (OR = 1.80, 95%CI = 1.37-2.36, *P*\<0.001) showed no statistical difference compared from the results described above (OR = 2.15, 95%CI = 1.71-2.70, *P*\<0.001). There was also no publication bias in studies evaluating response (*P* = 0.082). Thus, publication bias did not appear to affect our results.

Sensitivity Analysis
--------------------

Statistical analysis was conducted as described previously [@B23]. As shown in Figure [5](#F5){ref-type="fig"}, 6, and 7, the results were not affected by omitting individual studies in this meta-analysis, indicating that our results are reliable.

Trial Sequential analysis
-------------------------

We used the dominant model as an example to perform the TSA, which included eighteen trials with 2024 patients. The results showed the required information size was 1078, which meant our sample size was enough to get a robust conclusion about the UGT1A1\*28 polymorphism and chemotherapy response (Figure [8](#F8){ref-type="fig"}). The required sample sizes for determining the associations between UGT1A1 and diarrhea and neutropenia under the dominant model were 763 and 1162, respectively (data were not shown).

Discussion
==========

A couple of meta-analyses have investigated the relationships between the UGT1A1\*28 polymorphism and irinotecan-induced toxicity, severe diarrhea, and neutropenia. A study by Chen *et al*. in 2014 included six articles and found no statistically significant association between the UGT1A1\*28 polymorphism and neutropenia in Asians (OR = 1.67, 95%CI = 0.94-2.97) [@B65]. Liu et al.[@B66] conducted a meta-analysis of 16 articles and found that mCRC patients carrying the TA7/7 genotype had a higher risk of neutropenia and diarrhea in Caucasians. In contrast to previous studies, we evaluated 58 articles including 6087 cancer patients and performed stratified analyses based on ethnicity, study design, and cancer type. Statistical difference between the UGT1A1\*28 polymorphism and diarrhea was confirmed in Asian patients and mCRC patients under the five models. Individuals with at least mutation allele had a 1.71- and 5.34-fold greater risk of neutropenia than individuals carrying the wide genotype. Mutated genotypes of the UGT1A1\*28 polymorphism may lower the glucuronidation rates of SN-38 and lead to greater susceptibility to severe toxicities [@B25], [@B36].

Patients evaluated in this study, particularly mCRC patients with the TA6/7 and TA7/7 genotypes, may have severe diarrhea and neutropenia after irinotecan-induced chemotherapy. However, the UGT1A1\*28 TA6/6 and TA7/7 genotypes may show an increased treatment response according to our results. In contrast to our results, Xu *et al.*[@B67] observed different clinical responses in Ugyur patients with different UGT1A1\*28 polymorphism genotypes, but not in the Han population. Although the reduction of irinotecan was greater in patients with the TA7/7 or TA6/7 genotypes than the TA6/6 genotype, no difference in overall or progression-free survival between the two group patients were found by Dias *et al.*[@B68]. These results indicate that if the patients with mutant genotypes could tolerate the toxicities, irinotecan-based chemotherapy is a good choice for treatment. Additional studies of the treatment response should be carried out.

Previous meta-analyses included few than 20 studies and only focused on toxicities or chemotherapy response. In comparison with these studies, we included more research (58 studies) and investigated the associations of UGT1A1\*28 polymorphism with toxicities and chemotherapy effect. We also got a novel conclusion that patients with a higher risk of chemotherapy toxicities have a tendency to better response to chemotherapy. However, there were some limitations to our study. First, the number of studies of SCLC, mNSCLC, advanced GC, solid tumors, and other cancers were limited, and thus, larger sample sizes for a single tumor are needed to validate our results. Second, high heterogeneity existed among studies related to severe neutropenia under the recessive comparison. Although the number of patients could explain 25% of the heterogeneity, other influencing factors were not identified. Third, the studies we including selected different irinotecan doses in the chemotherapies, which may lead to some bias.

Conclusions
===========

In conclusion, we detected a significant relationship between the UGT1A1\*28 polymorphism and irinotecan-induced toxicity and response to irinotecan-based chemotherapy. This polymorphism may be useful as a detective index for cancer patients receiving irinotecan-based chemotherapy.
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###### 

Characteristics of the Studies Included in the Meta-Analysis

  Study              Year   Study design   Race        Cancer                                Mutation detection methods                 Regimen                                                               IRI dose (mg/m2)/schedule                                                   Population source   No. of patients   Age    ECOG   NOS
  ------------------ ------ -------------- ----------- ------------------------------------- ------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------- ----------------- ------ ------ -----
  Yan^8^             2016   R              Asian       mixed tumors                          PCR-Sanger sequence                        FOLFIRI, IRI + CDDP, IRI + BEV                                        125, 150 or 180 mg/m2                                                       S                   157               53     NR     8
  Xu^64^             2016   R              Asian       mCRC                                  Direct Sequencing                          FOLFIRI, IRI+CAP                                                      150mg/m2, every 2 or 3 weeks                                                S                   183               NR     0-1    9
  Gui^65^            2016   R              Asian       mCRC                                  SPR                                        FOLFIRI, IFL                                                          180mg/m2, every 2 or 3 weeks                                                S                   384               NR     0-2    8
  Wang^5^            2016   P              Asian       Advanced GC                           SPR                                        IRI+CDDP                                                              80 or 125mg/m2                                                              S                   40                54     0-2    8
  Li^4^              2016   P              Asian       mCRC                                  SPR                                        FOLFIRI, mCapeIRI, IRI                                                NR                                                                          M                   160               50     0-2    9
  Yang^63^           2015   R              Asian       pancreatic or biliary tract cancer    Direct Sequencing                          FOLFIRI, IRI alone                                                    180mg/m2, biweekly                                                          S                   48                56.2   0-1    7
  Peng^60^           2015   P              Asian       mCRC                                  Sequencing                                 FOLFIRI; mFOLFIRI                                                     180mg/m2, biweekly                                                          S                   208               59.8   0-3    7
  Wu^59^             2015   P              Asian       Advanced esophageal cancer            NR                                         IRI+PLA                                                               180mg/m2, every 3weeks                                                      S                   42                55     0-2    7
  Xu^3^              2015   NR             Asian       advanced OC                           PYRS                                       IRI+CDDP                                                              60mg/m2 IRI (d1, 8) every 3 weeks                                           S                   89                48     NR     7
  Xiao^9^            2015   R              Asian       SCLC                                  PYRS                                       IRI+CDDP/CBP/LOB                                                      60 mg/m2 (d1,8,15), every 4 weeks; 85mg/m2 (d1,8), every 3 weeks            S                   67                NR     0-2    8
  Shi^61^            2015   P              Asian       SCLC                                  Direct Sequencing                          IRI+CDDP                                                              65mg/m2 (d1, 8)                                                             M                   30                59     0-2    8
  Atasilp^10^        2015   R              Asian       mCRC                                  PYRS                                       FOLFIRI, FOLFIRI+CET, FOLFIRI+BEV, mFOLFIRI, IRI alone, IRI+CET/CAP   180mg/m2, biweekly; 100mg/m2                                                S                   44                6      0-2    7
  Chen^62^           2015   P              Asian       mNSCLC                                Sequencing                                 IRI+DDP                                                               100mg/m2, every 3 weeks                                                     S                   86                63     0-2    8
  Wang^35^           2015   P              Asian       mCRC                                  Sequencing                                 NR                                                                    NR                                                                          S                   111               NR     0-1    7
  Li^54^             2014   R              Asian       mCRC                                  PYRS                                       FOLFIRI, IRI + CET/BEV, IRI + RAL, IRI+ CAP                           180 mg/m2, every 2 or 3 weeks                                               S                   167               50     0-2    8
  Hirata^17^         2014   P              Asian       mCRC                                  SPR                                        FOLFIRI                                                               150mg/m2, biweekly                                                          M                   34                62     0-2    7
  Zhao^55^           2014   P              Asian       SCLC                                  Direct sequencing                          IRI+CDDP                                                              60mg/m2 (d1,8,15), every 3 weeks                                            S                   34                49     0-2    8
  Song^56^           2014   P              Asian       Advanced OC                           NR                                         IRI+PLA                                                               60mg/m2 (d1,8), every 3 weeks                                               S                   89                48     NR     8
  Zhang^57^          2014   P              Asian       mCRC                                  Sequencing                                 FOLFIRI, XELIRI, IRIR                                                 180mg/m2, biweekly; 200mg/m2, every 3weeks                                  S                   102               55     NR     8
  Xu^53^             2014   P              Asian       GC                                    Sequencing                                 NR                                                                    NR                                                                          S                   67                62.7   0-2    8
  Zhou^58^           2014   P              Asian       mCRC                                  SPR                                        IRI+5-FU/TMZ/CAP                                                      180mg/m2                                                                    S                   82                59     NR     8
  Zhou^52^           2013   P              Asian       gastrointestinal cancer               Direct Sequencing                          FOLFIRI                                                               180mg/m2, biweekly                                                          S                   94                58.5   0-1    8
  Hirasawa^50^       2013   R              Asian       cervical or ovarian cancer            Invader assay                              IRI+CDDP, IRI alone                                                   60 or 100mg/m2 (d1, 8, 15), every 4 weeks                                   S                   53                48     NR     7
  Gao^48^            2013   R              Asian       mCRC                                  Sanger Sequencing                          FOLFIRI, IRI alone or IRI+CET/CAP                                     180mg/m2                                                                    S                   276               55     NR     7
  Gao^49^            2013   R              Asian       advanced GC                           Sanger Sequencing                          IRI+CDDP, FOLFIRI, IRI alone, IRI+CET                                 180mg/m2                                                                    S                   42                53     NR     7
  Gao^49^            2013   R              Asian       advanced esophageal cancer            Sanger Sequencing                          IRI+CDDP, FOLFIRI, IRI alone, IRI+CET                                 130mg/m2; 180mg/m2                                                          S                   91                54     NR     7
  Qin^51^            2013   R              Asian       advanced gastrointestinal carcinoma   Sequencing                                 IRI, IRI+CDDP, IRI+5-FU                                               NR                                                                          S                   183               NR     NR     7
  Wang^45^           2012   NR             Asian       mCRC                                  Direct Sequencing                          FOLFIRI, IRI+LEU                                                      180mg/m2, biweekly; 125mg/m2 (d1, 8, 15, 22), every 6 weeks                 S                   130               52     0-2    7
  Zhang^46^          2012   P              Asian       mCRC                                  Direct Sequencing                          FOLFIRI, IRI+LEU                                                      180mg/m2, biweekly; 125mg/m2 (d1, 8, 15, 22), every 6 weeks                 S                   56                55.5   NR     8
  Lamas^34^          2012   R              Caucasian   mCRC                                  Fluorescent DNA length fragment analysis   FOLFIRI, FOLFIRI-CET, FOLFIRI-BEV, IRI+CET                            180mg/m2, biweekly                                                          S                   101               67     0-2    7
  Wang^47^           2012   P              Asian       mCRC                                  Sequencing                                 IFL, FOLFIRI                                                          125mg/m2, weekly;180mg/m2,biweekly                                          S                   180               54     0-2    7
  Shulman^33^        2011   R              Caucasian   mCRC                                  SPR                                        FOLFIRI, IFL, TEGAFIRI, XELIRI                                        U                                                                           M                   214               63.1   NR     8
  Okuyama^43^        2011   P              Asian       mCRC                                  SPR                                        FOLFIRI                                                               150mg/m2                                                                    S                   39                64     0-2    7
  Nakamura^42^       2011   P              Asian       mNSCLC                                Polyacrylamide gel electrophoresis         IRI+PAC, IRI+GEM                                                      50mg/m2 (d1, 8 and 15), every 4 weeks; 100mg/m2 (d1 and 8), every 3 weeks   S                   77                NR     0-1    8
  Park^44^           2011   P              Asian       mGC                                   Sequencing                                 S-1+IRI+OXA                                                           150mg/m2, every 3 weeks                                                     S                   44                54     0-2    7
  Mcleod^32^         2010   P              Caucasian   mCRC                                  PYRS                                       IRI+FU+LEU, IRI+OXA                                                   100-125mg/m2 (d1, 8, 15 and 22), every 6 weeks; 200mg/m2, every 3 weeks     M                   212               61     0-2    8
  Ji^41^             2010   R              Asian       mCRC                                  Sequencing                                 FOLFIRI                                                               180mg/m2, biweekly                                                          S                   64                NR     0-2    7
  Balibrea^31^       2010   P              Caucasian   mCRC                                  Sequencing                                 IRI+ 5-FU, IRI+5FU/LV                                                 80mg/m2, weekly; 180mg/m2, biweekly                                         M                   149               NR     0-2    8
  Han^39^            2009   P              Asian       mNSCLC                                SBE                                        IRI+CDDP                                                              65 or 80mg/m^2^ (d1 and 8), every 3 weeks                                   S                   107               58     0-2    7
  Onoue^40^          2009   P              Asian       Mixed tumors                          Direct Sequencing                          IRI alone; IRI+plat; IRI+ other anticancer agents, FOLFIRI            60-100mg/m2                                                                 S                   133               NR     0-1    7
  Ferraldeschi^18^   2009   P              Mixed       mCRC                                  SPR                                        IRI, FOLFIRI, IRI+VEGF inhibitor                                      350mg/m2, every 3 weeks; 180mg/m2, biweekly                                 S                   92                62.9   NR     8
  Rouits^29^         2008   R              Caucasian   mCRC                                  PYRS                                       FOLFIRI                                                               180mg/m2, biweekly                                                          S                   44                60     0-2    8
  Parodi^28^         2008   P              Caucasian   mCRC                                  SPR                                        FOLFIRI, mIFL, CapeIRI                                                125 or 180mg/m2, biweekly; 250mg/m2, every 3 weeks                          M                   110               NR     0-2    8
  Liu^16^            2008   R              Asian       mCRC                                  SPR                                        FOLFIRI                                                               180mg/m2, biweekly                                                          S                   128               NR     0-2    8
  Kweekel^15^        2008   R              Caucasian   mCRC                                  PYRS                                       IRI+CAP+OAX                                                           250 or 350mg/m2 (d1), every 3 weeks                                         M                   218               NR     0-2    8
  Wang^38^           2007   P              Asian       mCRC                                  SPR                                        FOLFIRI                                                               180mg/m2, biweekly                                                          M                   70                NR     0-3    8
  Ruzzo^30^          2007   P              Caucasian   mCRC                                  SPR                                        FOLFIRI                                                               180mg/m2, biweekly                                                          M                   146               61     NR     7
  Jada^37^           2007   NR             Asian       Mixed tumors                          SPR                                        IRI                                                                   375 mg/m2, every 3 weeks                                                    S                   45                55     0-2    7
  Cote^14^           2007   P              Caucasian   stage III colon cancer                SPR                                        LV5FU2+IRI                                                            180 mg/m2 (d1), every 2 weeks                                               M                   89                NR     NR     8
  Toffoli^11^        2006   P              Caucasian   mCRC                                  PYRS                                       mFOLFIRI or FOLFIRI                                                   180mg/m2 (d1), every 2 weeks                                                M                   250               60.6   0-2    8
  Massacesi^12^      2005   P              Caucasian   mCRC                                  Sequencing                                 IRI+RAL                                                               80 weekly (d1, 8, 15 and 22), every 5 weeks                                 M                   56                64     0-2    7
  Jong^13^           2006   P              Caucasian   Mixed tumors                          SPR                                        IR+NEO                                                                350mg/m2, every 3 weeks                                                     M                   52                58     0-2    8
  Han^36^            2006   P              Asian       mNSCLC                                Direct Sequencing                          IRI+CDDP                                                              80mg/m2 (d1 and 8), every 3 weeks                                           S                   81                NR     0-2    8
  Rouits^27^         2004   R              Caucasian   mCRC                                  PYRS                                       IRIFUFOL, FOLFIRI                                                     85mg/m2, weekly; 180mg/m2, biweekly                                         S                   73                62     0-2    8
  Marcuello^26^      2004   P              Caucasian   mCRC                                  SPR                                        IRI alone, IRI+TOM, IRI+5-FU, IRI+5-FU+leuc                           80mg/m2, weekly; 180mg/m2, biweekly;3 50mg/m2, every 3 weeks                S                   95                68     0-2    8
  Innocenti^67^      2004   P              Mixed       Mixed tumors                          SBE                                        IRI                                                                   350mg/m2, every 3 weeks                                                     S                   59                60     NR     7
  Font^66^           2003   NR             NR          mNSCLC                                Sequencing                                 IRI+DOC                                                               70mg/m2 (d1, 8 and 15), every 4 weeks                                       S                   47                55     0-2    7
  Iyer^25^           2002   P              Caucasian   Mixed tumors                          SPR                                        IRI                                                                   300mg/m2, every 3 weeks                                                     S                   20                NR     NR     8

R, analysis was planned retrospectively; P, analysis was planned prospectively; NR, Not reported; mCRC, metastatic colorectal cancer; GC, gastric cancer; SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer; SPR, Sizing of PCR products (analysis of fragment size); PYRS, Pyrosequencing; SBE, Single base prime extension assay; IRI, irinotecan; CDDP, cisplatin; BEV, bevacizumab; OXA, oxaliplatin; CET, cetuximab; PLA, platinum; IFL, FU+IRI; CAP, capecitabine; CBP, carboplatin; LOB, lobaplatin; RAL, raltitrexed; 5-FU, 5-fluorouracil; LV, leucovorin; GCB, gemicitabine; TOM, toumdex; DOC, docetaxel; PAC, paclitaxel; IFL, IRI+5-FU/LV; FOLFIRI, FOL stands for folinic acid, F for fluorouracil, IRIR for irinotecan+5-FU; S, single center; M, multicenter; ECOG, Estern Cooperative Oncology Group; NOS: Newcastle-Ottawa Scale.

###### 

Meta-analysis Results for diarrhea.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Compared genotype       Group           No. of studies   No. of participants   OR\            P         Test for heterogeneity   
                                                                                 (95%CI)                                           
  ----------------------- --------------- ---------------- --------------------- -------------- --------- ------------------------ -------
  TA6/7 vs. TA6/6         All             28               3435                  1.56\          \<0.001   0.175                    19.9%
                                                                                 (1.25-1.96)                                       

  mCRC                    16              2563             1.60\                 0.011          0.034     43.3%                    
                                                           (1.11-2.31)                                                             

  SCLC                    3               131              2.40\                 0.144          0.208     36.3%                    
                                                           (0.74-7.74)                                                             

  mNSCLC                  3               235              0.92\                 0.879          0.883     0.0%                     
                                                           (0.34-2.54)                                                             

  Asian                   18              2270             1.85\                 \<0.001        0.334     10.1%                    
                                                           (1.37-2.50)                                                             

  Caucasian               9               1118             1.28\                 0.117          0.136     35.3%                    
                                                           (0.91-1.80)                                                             

  Retrospective           13              2123             1.70\                 0.020          0.032     46.8%                    
                                                           (1.09-2.66)                                                             

  Prospective             12              1090             1.69\                 0.010          0.495     0.0%                     
                                                           (1.13-2.52)                                                             

  TA7/7 vs. TA6/6         All             17               2610                  3.97\          \<0.001   0.007                    51.7%
                                                                                 (1.88-8.38)                                       

  mCRC                    14              1172             3.53\                 0.003          0.004     57.5%                    
                                                           (1.54-8.09)                                                             

  Asian                   10              1805             8.98\                 \<0.001        0.152     32.0%                    
                                                           (5.21-15.47)                                                            

  Caucasian               7               805              1.09\                 0.807          0.259     22.3%                    
                                                           (0.56-2.13)                                                             

  Retrospective           9               1737             4.84\                 0.017          \<0.001   71.7%                    
                                                           (1.32-17.69)                                                            

  Prospective             7               743              2.86\                 0.009          0.555     0.0%                     
                                                           (1.30-6.30)                                                             

  TA6/7+7/7 vs. TA6/6     All             44               4868                  2.18\          \<0.001   0.003                    40.8%
                                                                                 (1.68-2.83)                                       

  SCLC                    3               131              3.95\                 0.009          0.115     53.8%                    
                                                           (1.42-11.01)                                                            

  mNSCLC                  4               321              1.24\                 0.582          0.560     0.0%                     
                                                           (0.58-2.65)                                                             

  Advanced OC             2               178              7.09\                 \<0.001        1.00      0.0%                     
                                                           (2.91-17.26)                                                            

  mCRC                    25              3477             1.96\                 \<0.001        0.005     47.3%                    
                                                           (1.42-2.70)                                                             

  Asian                   32              3607             2.74\                 \<0.001        0.132     22.2%                    
                                                           (2.21-3.40)                                                             

  Caucasian               11              1214             1.39\                 0.202          0.038     47.9%                    
                                                           (0.84-2.32)                                                             

  Retrospective           16              2359             2.17\                 0.001          0.001     62.0%                    
                                                           (1.36-3.49)                                                             

  Prospective             24              2198             2.12\                 \<0.001        0.263     14.3%                    
                                                           (1.62-2.79)                                                             

  TA7/7 vs. TA6/7+TA6/6   All             24               3175                  3.64\          \<0.001   \<0.001                  57.6%
                                                                                 (2.01-6.58)                                       

                          SCLC            2                64                    19.90\         0.004     0.832                    0.0%
                                                                                 (2.57-154.1)                                      

                          mCRC            17               2656                  3.16\          0.001     \<0.001                  64.1%
                                                                                 (1.61-6.19)                                       

                          Asian           13               1917                  8.64\          \<0.001   0.092                    36.3%
                                                                                 (4.14-18.04)                                      

                          Caucasian       10               1211                  1.62\          0.035     0.188                    27.8%
                                                                                 (1.03-2.53)                                       

                          Retrospective   11               2003                  2.06\          0.006     0.168                    32.5%
                                                                                 (1.23-3.44)                                       

                          Prospective     11               995                   2.92\          \<0.001   0.219                    26.2%
                                                                                 (1.64-5.21)                                       
  ----------------------------------------------------------------------------------------------------------------------------------------

mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer.

###### 

Meta-analysis Results for neutropenia.

  Compared genotype            Group   No. of studies   No. of participants   OR (95%CI)         P          Test for heterogeneity   
  ---------------------------- ------- ---------------- --------------------- ------------------ ---------- ------------------------ -------
  TA6/7 vs. TA6/6              All     32               3948                  1.71 (1.41-2.08)   \< 0.001   0.104                    24.8%
  mCRC                         19      2801             1.76 (1.40-2.23)      \<0.001            0.434      1.8%                     
  mNSCLC                       2       188              1.35 (0.55-3.34)      0.518              0.920      0.0%                     
  Asian                        21      2547             1.56 (1.07-2.27)      0.020              0.011      46.0%                    
  Caucasian                    10      1342             1.86 (1.34-2.60)      \<0.001            0.991      0.0%                     
  Retrospective                14      1468             1.90 (1.43-2.53)      \<0.001            0.201      23.3%                    
  Prospective                  15      1448             1.53 (1.15-2.05)      0.004              0.882      0.0%                     
  TA7/7 vs. TA6/6              All     27               3575                  5.34 (3.05-9.33)   \<0.001    0.003                    48.7%
  mCRC                         19      2801             5.07 (2.56-10.02)     \<0.001            0.001      59.3%                    
  Asian                        15      2154             4.77 (1.71-13.22)     0.003              0.001      62.6%                    
  Caucasian                    11      1362             5.39 (3.43-8.47)      \<0.001            0.342      10.7%                    
  Retrospective                12      1914             5.61 (3.58-8.82)      \<0.001            \<0.001    69.3%                    
  Prospective                  14      1531             5.81 (3.57-9.47)      \<0.001            0.291      14.8%                    
  TA6/7+7/7 vs. TA6/6          All     49               5232                  2.15 (1.71-2.70)   \<0.001    0.003                    39.5%
  mCRC                         26      3473             2.47 (1.86-3.27)      \<0.001            0.013      42.1%                    
  Advanced esophageal cancer   2       133              1.20 (0.48-3.05)      0.697              0.691      0.0%                     
  Advanced GC                  4       193              1.40 (0.64-3.06)      0.402              0.759      0.0%                     
  mNSCLC                       4       351              1.79 (0.97-3.33)      0.064              0.432      0.0%                     
  Asian                        35      3715             2.11 (1.54-2.89)      \<0.001            \<0.001    53.9%                    
  Caucasian                    13      1458             2.29 (1.69-3.08)      \<0.001            0.992      0.0%                     
  Retrospective                18      2318             2.52 (1.64-3.88)      \<0.001            \<0.001    59.3%                    
  Prospective                  29      2739             1.90 (1.53-2.35)      \<0.001            0.530      0.0%                     
  TA7/7 vs. TA6/6+6/7          All     28               3668                  4.12 (2.36-7.20)   \<0.001    \<0.001                  60.7%
  mCRC                         20      2894             3.70 (1.88-7.30)      \<0.001            \<0.001    69.4%                    
  Asian                        15      2154             4.16 (1.44-11.99)     0.008              \<0.001    68.9%                    
  Caucasian                    12      1455             3.39 (1.92-5.98)      \<0.001            0.057      42.7%                    
  Retrospective                12      1914             3.59 (1.05-12.28)     0.042              \<0.001    76.4%                    
  Prospective                  15      1624             4.10 (2.36-7.12)      \<0.001            0.088      35.1%                    

mCRC, metastatic colorectal cancer; GC, gastric cancer; mNSCLC, metastatic non-small-cell lung cancer.

###### 

Meta-analysis Results for response.

  Group           No. of studies   No. of participants   OR (95%CI)         P       Test for heterogeneity   
  --------------- ---------------- --------------------- ------------------ ------- ------------------------ -------
  All             18               2024                  1.20 (1.07-1.34)   0.016   0.082                    33.6%
  mCRC            12               1691                  1.24 (1.05-1.48)   0.014   0.060                    42.2%
  SCLC            2                64                    0.87 (0.57-1.33)   0.514   0.458                    0.0%
  mNSCLC          3                202                   1.08 (0.71-1.63)   0.726   0.127                    51.5%
  Asian           12               2270                  1.08 (0.82-1.42)   0.168   0.019                    51.7%
  Caucasian       5                1118                  1.23 (1.06-1.42)   0.006   0.669                    0.0%
  Retrospective   4                538                   1.54 (1.06-2.23)   0.022   0.060                    59.5%
  Prospective     12               1292                  1.07 (0.93-1.22)   0.343   0.511                    0.0%

mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer

###### 

P values for Begg\'s funnel plot and Egger\'s test for diarrhea and neutropenia.

                          Begg    Egger
  ----------------------- ------- -------
  Diarrhea                        
  TA6/7 vs. TA6/6         0.635   0.244
  TA7/7 vs. TA6/6         0.365   0.166
  TA6/7+TA7/7 vs. TA6/6   0.927   0.282
  TA7/7 vs. TA6/6+TA6/7   0.215   0.697
  Neutropenia                     
  TA6/7 vs. TA6/6         0.284   0.088
  TA7/7 vs. TA6/6         0.755   0.999
  TA6/7+TA7/7 vs. TA6/6   0.044   0.027
  TA7/7 vs. TA6/6+TA6/7   0.782   0.617
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